GlassScriptPhysician profile
Danielle R Bryant
NPI 1669254348
$1,902.84
in general payments reported to CMS, 2019-2025
24 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $1,040 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $330.00 | 2023-2024 | Urolift |
| Axonics, INC. | $299.46 | 2023-2024 | Axonics |
| Sumitomo Pharma America, INC. | $282.88 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $139.61 | 2024 | |
| Altathera Pharmaceuticals LLC | $129.02 | 2025 | Sotalol Hydrochloride |
| Bridgebio Pharma, INC. | $118.49 | 2025 | Attruby |
| Accord Healthcare, INC. | $74.42 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.21 | 2023-2025 | |
| Heartflow, INC. | $51.82 | 2025 | |
| Pfizer INC. | $51.59 | 2024-2025 | |
| Medtronic, INC. | $50.81 | 2024 | Corevalve Evolut R |
| Tolmar, INC. | $50.23 | 2024 | |
| Janssen Biotech, INC. | $45.83 | 2024-2025 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $36.09 | 2025 | |
| Progenics Pharmaceuticals, INC. | $32.12 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.58 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $21.48 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $17.85 | 2025 | Wainua |
| Antares Pharma, INC. | $17.63 | 2024 | Xyosted |
| Amgen INC. | $17.35 | 2025 | Repatha |
| Coloplast Corp | $16.32 | 2024 | |
| Astellas Pharma US INC | $15.28 | 2023 | Myrbetriq |
| Urogen Pharma, INC. | $13.96 | 2024 | |
| Merck Sharp & Dohme LLC | $13.81 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.